Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

[1]  M. Kurabayashi,et al.  Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  P. Marino,et al.  Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[3]  R. Hetzer,et al.  Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. , 2001, Journal of the American College of Cardiology.

[4]  P. Kalra,et al.  Absolute, not relative, changes are important when interpreting trial data. , 2001, Journal of the American College of Cardiology.

[5]  M. Kinoshita,et al.  Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[6]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[7]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[8]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[9]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[10]  M. Kinoshita,et al.  Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. , 1998, American heart journal.

[11]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[12]  A. Struthers,et al.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.

[13]  N. Farman,et al.  Tissue-Specific Expression of α and β Messenger Ribonucleic Acid Isoforms of the Human Mineralocorticoid Receptor in Normal and Pathological States , 1997 .

[14]  H. Hense,et al.  Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. , 1997, Heart.

[15]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[16]  C. Lang,et al.  Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. , 1995, The American journal of cardiology.

[17]  B. Pitt,et al.  ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). , 1995, European heart journal.

[18]  C. Delcayre,et al.  Biological determinants of aldosterone-induced cardiac fibrosis in rats. , 1995, Hypertension.

[19]  A. Struthers.  Aldosterone escape during ACE inhibitor therapy in chronic heart failure. , 1995, European heart journal.

[20]  S. Jensen,et al.  The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. , 1995, The American journal of cardiology.

[21]  N. Farman,et al.  Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. , 1995, Circulation.

[22]  H. Eichler,et al.  Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. , 1995, The American journal of cardiology.

[23]  M. Amrani,et al.  Extension of native aortic valve endocarditis: surgical considerations. , 1995, European heart journal.

[24]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[25]  K. Weber,et al.  Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. , 1994, Journal of molecular and cellular cardiology.

[26]  R. Dilley,et al.  Mineralocorticoids, hypertension, and cardiac fibrosis. , 1994, The Journal of clinical investigation.

[27]  M. Kinoshita,et al.  Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.

[28]  J. Parameshwar,et al.  The role of calcium antagonists in the treatment of chronic heart failure. , 1993, European heart journal.

[29]  U. Puistola,et al.  Effect of gynecological operations on the serum concentration of the aminoterminal propeptide of type III procollagen , 1993, Acta obstetricia et gynecologica Scandinavica.

[30]  J. Kaufman,et al.  Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. , 1993, The American journal of cardiology.

[31]  E. Baulieu,et al.  Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. , 1992, Circulation research.

[32]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[33]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[34]  W. Meyer,et al.  Aldosterone and dexamethasone binding in human arterial smooth muscle cells. , 1987, Journal of hypertension.

[35]  B. W. East,et al.  Captopril in heart failure. A double blind controlled trial. , 1984, British heart journal.

[36]  J. Staessen,et al.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.

[37]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.

[38]  A. de la Sierra,et al.  Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with aldosterone and the increase in sodium-proton exchanger activity. , 1993, European heart journal.

[39]  T. Horio,et al.  Brain natriuretic peptide as a cardiac hormone in essential hypertension. , 1992, The American journal of medicine.

[40]  E. Kékes.  Captopril in heart failure. , 1988, Acta physiologica Hungarica.